Jie-Jian Chen
Overview
Explore the profile of Jie-Jian Chen including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
6
Citations
62
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Zhong X, Shi M, Liu H, Chen J, Wang T, Lin M, et al.
Pharm Dev Technol
. 2020 Oct;
26(1):21-29.
PMID: 33070673
Multidrug resistance (MDR) is a serious challenge in chemotherapy and also a major threat to breast cancer treatment. As an intracellular energy factory, mitochondria provide energy for drug efflux and...
2.
Guo W, Zhang Z, Wei Q, Zhou Y, Lin M, Chen J, et al.
Biomacromolecules
. 2019 Dec;
21(2):444-453.
PMID: 31851512
Self-assembled peptide nanofibers have been widely studied in cancer nanotherapeutics with their excellent biocompatibility and low toxicity of degradation products, showing the significant potential in inhibiting tumor progression. However, poor...
3.
Wang T, Wei Q, Zhang Z, Lin M, Chen J, Zhou Y, et al.
Biomater Sci
. 2019 Nov;
8(1):118-124.
PMID: 31777865
On account of the biological significance of self-assembling peptides in blocking the cellular mass exchange as well as impeding the formation for actin filaments resulting in program cell death, stimuli-responsive...
4.
Zhong X, Xu W, Wang Z, Guo W, Chen J, Guo N, et al.
Drug Dev Ind Pharm
. 2019 Jul;
45(9):1556-1564.
PMID: 31271317
This study was aimed to develop DOX-TPP loaded acetal-PEG-PCCL micelles to improve the clinical efficacy of drug resistance tumor. Chemotherapy is one of the main treatments for breast cancer but...
5.
Liu H, Guo N, Guo W, Huang-Fu M, Vakili M, Chen J, et al.
Acta Pharmacol Sin
. 2018 Jun;
39(10):1681-1692.
PMID: 29849132
Breast cancer is the leading cause of cancer-related death for women, and multidrug resistance (MDR) is the major obstacle faced by chemotherapy for breast cancer. We have previously synthesized a...
6.
Liu H, Guo N, Wang T, Guo W, Lin M, Huang-Fu M, et al.
Mol Pharm
. 2018 Jan;
15(3):882-891.
PMID: 29357260
Multidrug resistance (MDR) is the major obstacle for chemotherapy. In a previous study, we have successfully synthesized a novel doxorubicin (DOX) derivative modified by triphenylphosphonium (TPP) to realize mitochondrial delivery...